Summary The anti-tumour actvity of methyl-p-cyckxdextrin (MEBCD), a cydic oligosaccharide known for its interaction with the plasma membrane, was investigated in vitro and in vivo and compared with that of doxorubicin (DOX) in the human tumour models MCF7 breast carcinoma and A2780 ovanan carcinoma. In vitro proliferation was assessed using the MTT assay. In vivo studies were carmied out using xenografted Swiss nude mice injected weeldy i.p. with MEBCD at 300 or 800 mg kg-, or DOX at 2 mg kg-', durng 2 months. Undrer these conditions, MEBCD was active against MCF7 and A2780 cell lines and tumour xenografts. For each tumour model, the tumoral volume of the xenografted mice treated with MEBCD was at least twofold reduced compared wit the control group. In the MCF7 model, MEBCD (800 mg kg-') was more active than DOX (2 mg kg-1). After 56 days of treatnent with MEBCD, no toxicologically meaningful differences were observed in macroscopic and microscopic parameters compared with controls. The accumulation of MEBCD in normal and tumour tssues was also assessed using a chromatographic method. Results indicated that after a single injection of MEBCD, tumour, liver and kidneys accumulated the highest concentrations of MEBCD. These results provided a basis for the potental therapeutic application of MEBCD in cancer therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.